Insider Trading May 14, 2026 08:10 PM

Klaviyo Executive Activity and Valuation Assessment Amid Mixed Analyst Signals

Co-CEO Andrew Bialecki executes stock sale via 10b5-1 plan while company reports strong Q1 earnings, leading to mixed analyst price target adjustments.

By Derek Hwang KVYO

Andrew Bialecki, Co-Chief Executive Officer and director of Klaviyo, Inc. (NASDAQ:KVYO), recently reported a significant stock sale worth approximately $2.92 million on May 12, 2026. This transaction was executed through a prearranged Rule 10b5-1 trading plan. The report details Bialecki's holdings and provides context regarding the company's recent financial performance for Q1 2026, which exceeded expectations. Despite the strong earnings results, the stock has experienced significant volatility, leading major investment banks to adjust their price targets while maintaining ratings.

Klaviyo Executive Activity and Valuation Assessment Amid Mixed Analyst Signals
KVYO

Key Points

  • Insider selling activity by Co-CEO Andrew Bialecki via a prearranged plan occurred despite recent strong quarterly earnings.
  • Klaviyo reported first quarter 2026 financials that surpassed expectations, with EPS at $0.22 and revenue at $358 million.
  • Analyst coverage is mixed: while the company shows signs of being undervalued based on certain assessments, major firms lowered price targets citing guidance deceleration.

The recent insider trading activity at Klaviyo, Inc. (NASDAQ:KVYO) centers on Andrew Bialecki, who serves as Co-Chief Executive Officer and a director for the company. On May 12, 2026, Mr. Bialecki reported divesting approximately $2.92 million worth of company shares. These transactions were systematically managed under a Rule 10b5-1 trading plan that he had initially established on May 20, 2025.

Specifically, the report indicates that Bialecki sold a total of 200,000 shares classified as Series A Common Stock. These dispositions occurred across multiple transactions, with weighted average sale prices ranging from $14.46 to $14.97 per share, totaling $2,921,928 in value. This reported selling activity takes place while Klaviyo's stock price is trading near $14.34, which is close to its 52-week low of $13.53. Over the past year, shares have seen a decline of 59%. Despite this recent downward trend, analysis from InvestingPro suggests that the underlying value may be undervalued, citing its Fair Value assessment and placing it among opportunities designated as 'Most Undervalued.' The company currently maintains a market capitalization of $4.26 billion.

In addition to the sale of Series A shares, Bialecki also executed a conversion transaction on the same day, converting 200,000 shares of Series B Common Stock into an equal number of Series A Common Stock. It is noted that each share of Klaviyo's Series B Common Stock retains the flexibility to convert into one share of Series A Common Stock at any time and has no expiration date.

Reviewing Current Share Holdings

Following these reported transactions, an examination of Mr. Bialecki's current holdings reveals that he directly holds 67,144,118 shares of Series B Common Stock. His indirect ownership structure is more complex, encompassing various trusts and family members. Specifically, the Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023 accounts for 7,517,410 shares. The Elizabeth L. Bialecki Irrevocable GST Trust of 2023 holds 517,006 shares, and the Andrew P. Bialecki Irrevocable GST Trust of 2023 also accounts for 517,006 shares. Furthermore, his spouse indirectly holds an additional 43,218 shares.

Financial Performance Context

The context for these market movements is provided by Klaviyo Inc.'s financial reporting for the first quarter of 2026. The company released results that surpassed analyst expectations across key metrics. For earnings per share (EPS), Klaviyo posted $0.22, which exceeded the anticipated figure of $0.20. Furthermore, revenue reached $358 million, outperforming the expected $348.6 million. These positive financial outcomes were initially followed by a modest uptick in the company's stock price during aftermarket trading.

Analyst Divergence and Price Targets

Despite the strong earnings report, analyst sentiment displayed noticeable divergence regarding valuation and future guidance. Stifel adjusted its previous price target for Klaviyo downward from $35 to $28. The firm cited deceleration observed in the company's guidance while simultaneously maintaining a 'Buy' rating. Similarly, Piper Sandler reduced its price target from $30 to $26. This adjustment was accompanied by concerns regarding profit margins, though the investment bank maintained an 'Overweight' rating. These multiple adjustments underscore a current focus among management and analysts on achieving greater precision and accuracy in future financial forecasting.

The stock has demonstrated recent volatility; at one point, it saw a notable increase of 18% over five days, and more broadly, rose 43% from its lows recorded in April. This combination of robust underlying financials and cautious, adjusted analyst expectations creates a complex picture for market participants assessing the company's immediate trajectory.

Risks

  • Guidance Deceleration: Stifel noted a slowdown in Klaviyo's guidance, leading to a reduction in its price target from $35 to $28. This suggests potential headwinds in future operational planning.
  • Margin Concerns: Piper Sandler expressed specific concerns over the company's margins, contributing to a lowered price target from $30 to $26. This points to possible pressure on profitability.
  • Market Weakness Contrast: The stock has traded near its 52-week low of $13.53 and is down 59% over the past year, indicating significant underlying market weakness despite strong Q1 results.

More from Insider Trading

WillScot Director Reports Significant Stock Sales Amid Market Valuation Observations May 14, 2026 Analysis of Insider Transactions and Financial Performance at Innodata Inc. May 14, 2026 Protagonist Therapeutics CEO Sells Shares Following Option Exercise Amid Analyst Optimism May 14, 2026 Shattuck Labs' CTO Sells Shares Following Stock Surge Amid Positive Drug Candidate News May 14, 2026 Insider Activity Highlights Buying Spree by Biglari Chairman's Fund in BH Stock May 14, 2026